The tweet was deleted by the author.
But we saved everything 🙂.
Arvinas announced plans to present preclinical data for its PROTAC HPK1 degrader as well as details on the design of its upcoming Phase 1 2 trial at SITC2026 next week.
The company signaled continued advancement in its drug discovery program and early clinical development pipeline.
View post on X Loading...
Arvinas previously announced the first PROTAC protein degrader approval, expanding its portfolio in targeted protein degradation therapies. The company also reinstated its Early Career Researcher Award, offering a $25,000 grant to support emerging scientists in the field, according to an earlier report on the award announcement. These initiatives indicate Arvinas' continued investment in both pipeline development and scientific research.